ライフサイエンスコーパス: very low density

1 mental duplication, the mouse sequence has a very low density.

2 factor for entry of HCVfrg subpopulations of very low density.

3 cause of increased assembly and secretion of very low density apolipoprotein B (apoB) and triglycerid

4 These materials have very low densities between 1.12 and 1.37 g cm(-3) and th

5 nzania than previously thought and that even very low-density chimpanzee populations can be infected

6 We show a very low-density, deep-seated upwelling that ascends ben

7 HCV- RNA was measured in the very-low-density fraction (VLDF, d < 1.025 g/mL) before

8 We also observed a minor population of very-low-density, >100-nm-diameter vesicular particles t

9 st in around 2.8% of the region, and live in very low densities in most of the areas.

10 , the S cones had an inverse topography with very low densities in the central retina and highest den

11 ing the catabolism of autologous (125)I-apoB very low density/intermediate density lipoprotein (VLDL/

12 phospholipids, that were distributed in the very low density/intermediate density/low-density lipopr

13 lipoprotein substrate triglyceride content (very low density lipoprotein >> LDL > high density lipop

14 Abnormalities in very low density lipoprotein (VLDL) assembly and secreti

15 ridemia was due largely to overproduction of very low density lipoprotein (VLDL) by the liver, a norm

16 Nascent very low density lipoprotein (VLDL) exits the endoplasmi

17 uptake of low density lipoprotein (LDL) and very low density lipoprotein (VLDL) particles by a singl

18 The transport of nascent very low density lipoprotein (VLDL) particles from the e

19 In contrast, the very low density lipoprotein (VLDL) pathway, which is re

20 This antitumor mechanism may involve the very low density lipoprotein (VLDL) receptor because the

21 incubations of apoA-I(-)(/)(-) apoE(-)(/)(-) very low density lipoprotein (VLDL) resulted in a 3-fold

22 intrahepatic triglyceride (IHTG) content and very low density lipoprotein (VLDL) triglyceride (TG) se

23 correlated to insulin resistance and plasma very low density lipoprotein (VLDL) triglycerides concen

24 sma apolipoprotein B yet increased levels of very low density lipoprotein (VLDL) triglycerides, sugge

25 erum triglycerides primarily associated with very low density lipoprotein (VLDL) with no difference i

26 (LDL) density lipoprotein as lipid donor to very low density lipoprotein (VLDL), and the preference

27 cells do not express MTP and cannot secrete very low density lipoprotein (VLDL), yet they do not acc

28 ted apoE in accounting for the difference in very low density lipoprotein (VLDL)-induced adipocyte tr

29 oth human high density lipoprotein (HDL) and very low density lipoprotein (VLDL).

30 toma cells can mediate binding and uptake of very low density lipoprotein (VLDL).

31 ed for the hepatic assembly and secretion of very low density lipoprotein (VLDL).

32 h a Golgi-dependent mechanism while bound to very low density lipoprotein (vLDL).

33 In contrast, serum levels of very low density lipoprotein (VLDL)/low density lipoprot

34 Atherogenic very low density lipoprotein and intermediate density li

35 tion and considerably decreases synthesis of very low density lipoprotein and its secretion in both l

36 of a subset of apolipoproteins implicated in very low density lipoprotein and triglyceride metabolism

37 a massive uptake of yolk precursors such as very low density lipoprotein and vitellogenin.

38 This tempers triglyceride availabiity for very low density lipoprotein assembly and allows homeost

39 sulfate and 2-O-sulfate groups did not block very low density lipoprotein binding and uptake in isola

40 1-tg mice had increased secretion of hepatic very low density lipoprotein but maintained plasma trigl

41 terols isolated from liver, bile, and plasma very low density lipoprotein by a variant of ISA designe

42 C), low density lipoprotein cholesterol, and very low density lipoprotein cholesterol (VLDL-C) assess

43 After 7 days, triglyceride (TG) levels and very low density lipoprotein cholesterol (VLDLc) levels

44 measurements revealed a 3.6-fold decrease of very low density lipoprotein cholesterol in serum and a

45 d fasting levels of plasma triglycerides and very low density lipoprotein cholesterol, and increased

46 rcumference, triglycerides, body mass index, very low density lipoprotein cholesterol, lipoprotein A,

47 first and rate-limiting step in chylomicron/very low density lipoprotein clearance at the luminal su

48 enesis of both apoB48 and apoB100-containing very low density lipoprotein in addition to a phospholip

49 ecombinant Angptl4 causes increase of plasma very low density lipoprotein levels by inhibition of lip

50 reassembly of triacylglycerols that lipidate very low density lipoprotein particles as part of a hepa

51 at the assembled virions piggy-back onto the very low density lipoprotein particles for secretion.

52 s C virus (HCV) particles assemble along the very low density lipoprotein pathway and are released fr

53 Activation of very low density lipoprotein receptor (VLDLR) and apolip

54 Reelin signals via the lipoprotein receptors very low density lipoprotein receptor (VLDLR) and apolip

55 to apolipoprotein E receptor 2 (ApoER2) and very low density lipoprotein receptor (VLDLR) and is int

56 We discovered that miR-200c targets the very low density lipoprotein receptor (Vldlr) and its li

57 ApoE Receptor 2 (ApoER2) and the very low density lipoprotein receptor (VLDLR) are type I

58 The very low density lipoprotein receptor (VLDLR) is a membe

59 Previously, we have shown that very low density lipoprotein receptor (VLDLR) is virtual

60 induced choroidal neovascularization and the very low density lipoprotein receptor (Vldlr)-knockout m

61 scular entothelial growth factor [VEGF], and very low density lipoprotein receptor [VLDLR]) were test

62 Very low density lipoprotein receptor gene knock-out (Vl

63 ails of the lipoprotein receptors ApoER2 and very low density lipoprotein receptor through an amino-t

64 y, including the receptors ApoER2 and VLDLR (very low density lipoprotein receptor) and the adapter p

65 r domains of apolipoprotein E receptor 2 and very low density lipoprotein receptor, Dab1 is preferent

66 ells via apolipoprotein E receptor 2 and the very low density lipoprotein receptor, resulting in the

67 (d), approximately 30 nM) but not to soluble very low density lipoprotein receptor.

68 ticles such as very low density lipoprotein, very low density lipoprotein remnants, and intermediate-

69 lls to acetylated low-density lipoprotein or very low density lipoprotein resulted in a time- and con

70 and increased secretion of triglyceride-rich very low density lipoprotein resulting in hypertriglycer

71 els were associated with both a reduction in very low density lipoprotein secretion and an increase i

72 ombined effect of inhibition of lipogenesis, very low density lipoprotein secretion and export of tri

73 Despite increased very low density lipoprotein secretion, apoB/BATless mic

74 cal increase in both hepatic lipogenesis and very low density lipoprotein secretion.

75 nhibiting hepatic triglyceride synthesis and very low density lipoprotein secretion.

76 er of surface components of chylomicrons and very low density lipoprotein to high density lipoprotein

77 -IV, C-II, and C-III and increases serum and very low density lipoprotein triglyceride levels.

78 , via mitochondrial beta-oxidation and VLDL (very low density lipoprotein) secretion, causes excessiv

79 olesterol into apoB-containing lipoproteins (very low density lipoprotein, intermediate density lipop

80 ewly formed lipid droplets, and yolk-derived very low density lipoprotein, shown to be efficiently en

81 , where rs964184 was associated with various very low density lipoprotein, triglyceride, and high-den

82 (a), and triglyceride-rich particles such as very low density lipoprotein, very low density lipoprote

83 ich lipoproteins, including chylomicrons and very low density lipoprotein, which is the precursor to

84 protein distribution preference of apoE4 for very low density lipoprotein-sized particles.

85 Mttp produced a dramatic reduction in plasma very low density lipoprotein-TG and virtually eliminated

86 the increase in LPL activity, the uptake of very low density lipoprotein-TG is markedly reduced in a

87 ants caused only a small increase in hepatic very low density lipoprotein-triglyceride secretion.

88 ajor role in promoting uptake of circulating very low density lipoprotein-triglycerides (VLDL-TGs) in

89 without significant changes in plasma TG or very low density lipoprotein.

90 ype EL, whereas LPL only mediated binding of very low density lipoprotein.

91 protein B-100 (apoB-100), and beta-migrating very low-density lipoprotein (beta-VLDL) particles, whic

92 ngivalis levels was directly correlated with very low-density lipoprotein (P = 0.03) and triglyceride

93 oprotein (HDL(NMR)), 1.71 (1.38 to 2.12) for very low-density lipoprotein (VLDL(NMR)), and 2.25 (1.80

94 00014; African Americans P = 0.00417), large very low-density lipoprotein (VLDL) (Caucasians P = 0.00

95 the accumulation of free cholesterol in the very low-density lipoprotein (VLDL) and HDL region, and

96 apo) E between lipoprotein particles such as very low-density lipoprotein (VLDL) and high-density lip

97 idemia, the esterification of cholesterol of very low-density lipoprotein (VLDL) and high-density lip

98 usly found that EL is capable of hydrolyzing very low-density lipoprotein (VLDL) and LDL lipids ex vi

99 Very low-density lipoprotein (VLDL) and LDL plasma level

100 ) and the apolipoprotein B (apoB)-containing very low-density lipoprotein (VLDL) and low-density lipo

101 hydrolase (Ces3/TGH) participates in hepatic very low-density lipoprotein (VLDL) assembly and in adip

102 de (TG) levels resulting both from increased very low-density lipoprotein (VLDL) clearance and decrea

103 n decreased cholesterol levels and decreased very low-density lipoprotein (VLDL) fractions.

104 Increased production of very low-density lipoprotein (VLDL) is a critical featur

105 TGs, hepatosteatosis, and secrete lipid-poor very low-density lipoprotein (VLDL) lacking arachidonoyl

106 monstrate that Sort1 alters plasma LDL-C and very low-density lipoprotein (VLDL) particle levels by m

107 ting impaired ER-to-Golgi trafficking of pre-very low-density lipoprotein (VLDL) particles.

108 NDGA inhibited very low-density lipoprotein (VLDL) secretion by affecti

109 ic pathways, such as triglyceride synthesis, very low-density lipoprotein (VLDL) secretion, and fatty

110 attenuation of hepatic steatosis, increased very low-density lipoprotein (VLDL) secretion, and impro

111 erized by a 3-fold higher liver secretion of very low-density lipoprotein (VLDL) that had apoC-III bu

112 mbination of size and concentrations of LDL, very low-density lipoprotein (VLDL), and high-density li

113 ined the lipidation and secretion of nascent very low-density lipoprotein (VLDL), finding that liver

114 experiments demonstrate that the LDLR has a very low-density lipoprotein (VLDL)-induced, FDNPVY-inde

115 ent reversed tumor necrosis factor alpha and very low-density lipoprotein (VLDL)-stimulated endotheli

116 apoCII levels and increased apoB48 levels in very low-density lipoprotein (VLDL)/intermediate-density

117 nmol/L versus TT, 57.0+/-4.5 nmol/L; P=0.03) very low-density lipoprotein and chylomicron particle nu

118 ations, the variant was also associated with very low-density lipoprotein and high-density lipoprotei

119 ein B (apoB), the major protein component of very low-density lipoprotein and low-density lipoprotein

120 concentration of proatherogenic lipoproteins very low-density lipoprotein and low-density lipoprotein

121 Very low-density lipoprotein and triglyceride concentrat

122 actor of 5 for the ratio of triglycerides to very low-density lipoprotein cholesterol (TG:VLDL-C); ho

123 l fibres reviewed reduced total cholesterol, very low-density lipoprotein cholesterol (VLDL-C) and LD

124 patient-specific ratios of triglycerides to very low-density lipoprotein cholesterol.

125 acylglycerols, apolipoproteins A-I and B, or very low-density lipoprotein cholesterol.

126 ssociation results for medium and very large very low-density lipoprotein composition are unlikely to

127 y lipoprotein levels and increased uptake of very low-density lipoprotein into Cxcr7-expressing white

128 uction in fasting plasma triacylglycerol and very low-density lipoprotein level coupled with slight i

129 Treatment with CCX771 reduced circulating very low-density lipoprotein levels but not low-density

130 0% less body weight gain and lower serum and very low-density lipoprotein levels of triglycerides but

131 ether inhibition of PCSK9 has any effects on very low-density lipoprotein or intermediate-density lip

132 The very low-density lipoprotein receptor (VLDLR) knockout (

133 le pathways including through the receptors, Very low-density lipoprotein receptor (Vldlr), Apolipopr

134 Mice deficient in another Reelin receptor, very low-density lipoprotein receptor (VLDLR), had norma

135 gnaling pathway that requires its receptors, very low-density lipoprotein receptor and apolipoprotein

136 ation and vascular leakage in the eyecups of very low-density lipoprotein receptor knockout mice, a m

137 Very low-density lipoprotein receptor mutant mice (Vldlr

138 uncation disrupts an interaction with VLDLR (very low-density lipoprotein receptor), while the APOER2

139 an interaction with the RELN receptor VLDLR (very low-density lipoprotein receptor); this was confirm

140 l blood vessels invading photoreceptors: the very low-density lipoprotein receptor-deficient (Vldlr(-

141 miR-34a inhibits very low-density lipoprotein secretion and promotes live

142 Blocking hepatic very low-density lipoprotein secretion through genetic o

143 genes involved in fatty acid beta-oxidation, very low-density lipoprotein secretion, and transcriptio

144 Choline metabolism is important for very low-density lipoprotein secretion, making this nutr

145 cal mechanisms and consequences of defective very low-density lipoprotein secretion.

146 and inadequate increases in IHTG export via very low-density lipoprotein secretion.

147 nover, which drives hepatic triglyceride and very low-density lipoprotein synthesis.

148 Uptake of DiI-labeled very low-density lipoprotein to adipose tissue was deter

149 ect has been shown to be caused by decreased very low-density lipoprotein triglyceride secretion rate

150 incorporation into palmitate of circulating very low-density lipoprotein triglyceride.

151 emic free fatty acids (FFA) into circulating very low-density lipoprotein triglycerides (VLDL-TGs) un

152 oxidation and export (as triglyceride within very low-density lipoprotein).

153 pairment in their catabolism of remnants and very low-density lipoprotein, an effect that was entirel

154 6449) has been associated with triglyceride, very low-density lipoprotein, and high-density lipoprote

155 nonexchangeable protein in chylomicrons and very low-density lipoprotein-derived lipoprotein particl

156 pact of anti-miR-33 therapy on the levels of very low-density lipoprotein-triglycerides (VLDL-TAG).

157 rosclerosis, considering they also had lower very low-density lipoprotein/low-density lipoprotein cho

158 No changes in plasma levels of very low-density lipoprotein/low-density lipoprotein, hi

159 in (HDL), low-density lipoprotein (LDL), and very-low density lipoprotein (VLDL), play a critical rol

160 structural diversity in olive oil and human very-low density lipoprotein.

161 ptotic activity of HDL is inhibited by APOE4 very-low-density lipoprotein (APOE4-VLDL) in endothelial

162 protein subclasses were shifted toward lower very-low-density lipoprotein (P<0.001) and higher large

163 Cardiac utilisation of very-low-density lipoprotein (VLDL) and chylomicrons (CM

164 Very-low-density lipoprotein (VLDL) and chylomicrons (CM

165 fects were mainly on serum triglycerides and very-low-density lipoprotein (VLDL) and its subclasses,

166 NT ASO exhibited a significant impairment in very-low-density lipoprotein (VLDL) binding that was ent

167 protein, high-density lipoprotein (HDL), and very-low-density lipoprotein (VLDL) cholesterol levels.

168 36 had significantly lower plasma TC, LDL-C, very-low-density lipoprotein (VLDL) cholesterol, and MDA

169 in plasma low-density lipoprotein (LDL) and very-low-density lipoprotein (VLDL) discriminated dengue

170 the notion that HCV coopts the secretion of very-low-density lipoprotein (VLDL) for its egress.

171 y reduced triglycerides and large and medium very-low-density lipoprotein (VLDL) particle concentrati

172 patitis C virus (HCV) uses components of the very-low-density lipoprotein (VLDL) pathway for assembly

173 hepatic triglycerides (TAG) associated with very-low-density lipoprotein (VLDL) play a major role in

174 FPIct) has been shown to be a ligand for the very-low-density lipoprotein (VLDL) receptor, we hypothe

175 ght but is associated with increased hepatic very-low-density lipoprotein (VLDL) secretion and elevat

176 glyceride content by threefold and decreased very-low-density lipoprotein (VLDL) secretion by 50%.

177 oaches, we demonstrate that vigilin controls very-low-density lipoprotein (VLDL) secretion through th

178 TG content, we measured hepatic lipogenesis, very-low-density lipoprotein (VLDL) secretion, and lipid

179 Genes for very-low-density lipoprotein (VLDL) synthesis (microsoma

180 rcise prevents fructose-induced increases in very-low-density lipoprotein (VLDL) triglycerides by dec

181 spectrometric analysis suggested that serum very-low-density lipoprotein (VLDL) was responsible for

182 -48-containing TRLs and apo B-100-containing very-low-density lipoprotein (VLDL), as well as on the e

183 inal) in lipoprotein fractions [chylomicron, very-low-density lipoprotein (VLDL), LDL, high-density l

184 weeks) for 8 weeks on the plasma kinetics of very-low-density lipoprotein (VLDL)-apolipoprotein B-100

185 ic and proteomic profiles implicated these 3 very-low-density lipoprotein (VLDL)-associated apolipopr

186 a marked suppression of the plasma levels of very-low-density lipoprotein (VLDL)-associated triglycer

187 e important for HCV cell-to-cell spread, but very-low-density lipoprotein (VLDL)-containing mouse ser

188 e observed strong positive associations with very-low-density lipoprotein (VLDL)-lipoproteins, VLDL-c

189 Very-low-density lipoprotein (VLDL)-triacylglycerols and

190 uh7 cells via pathways distinct from that of very-low-density lipoprotein (VLDL).

191 TG) and apolipoprotein C-III levels, and low very-low-density lipoprotein (VLDL)/high high-density li

192 Indeed, LpL mediated hydrolysis of very-low-density lipoprotein activated PPARalpha in card

193 ng aetiology via extensive associations with very-low-density lipoprotein and triglyceride metabolism

194 D-PDMP affected very-low-density lipoprotein catabolism by increasing th

195 2 to 63.1%), LDL cholesterol (1.3 to 32.9%), very-low-density lipoprotein cholesterol (27.9 to 60.0%)

196 at individual CpGs as a function of fasting very-low-density lipoprotein cholesterol and triglycerid

197 , hypoxia increased hepatic SCD-1 and plasma very-low-density lipoprotein cholesterol levels and indu

198 lic blood pressure, triglyceride levels, and very-low-density lipoprotein cholesterol levels, lesser

199 mean concentrations of triglycerides (TGs), very-low-density lipoprotein cholesterol, and glucose we

200 triacylglycerols, apolipoprotein A-I and B, very-low-density lipoprotein cholesterol, and lipoprotei

201 of macrophage LRP decreased uptake of (125)I-very-low-density lipoprotein compared with wild-type cel

202 significantly change serum triglycerides or very-low-density lipoprotein concentrations.

203 er high-density lipoprotein lipids and lower very-low-density lipoprotein lipids, glucose levels, bra

204 n, 95% confidence interval 3.48-6.78), other very-low-density lipoprotein measures, and branched-chai

205 0.70, 95% CI 0.65-0.76, p = 2x10(-)(1)(8)), very-low-density lipoprotein particle size (HR 0.69, 95%

206 rly in therapy, whereas TG concentration and very-low-density lipoprotein particle size decreased con

207 DL particles (0.77, 0.60-0.99, P=0.045), and very-low-density lipoprotein particles (0.78, 0.61-0.99,

208 mall LDL (0.78, 0.61-1.00, P=0.05) and small very-low-density lipoprotein particles (0.78, 0.62-0.99,

209 s, LDL particles, and select subfractions of very-low-density lipoprotein particles and LDL particles

210 zed with increasing levels of triglycerides, very-low-density lipoprotein particles, LDL-P, sdLDL-C,

211 e appearance in nonesterified fatty acid and very-low-density lipoprotein pools was negatively associ

212 ing, quantitative polymerase chain reaction, very-low-density lipoprotein production, adenovirus over

213 revealed a point mutation, c.2239C>T, in the very-low-density lipoprotein receptor (Vldlr) gene.

214 Very-low-density lipoprotein receptor (VLDLR) in knockou

215 Very-low-density lipoprotein receptor (VLDLR) is a multi

216 The very-low-density lipoprotein receptor (VLDLR) negatively

217 Very-low-density lipoprotein receptor (Vldlr), which is

218 retinopathy and another angiogenic model of very-low-density lipoprotein receptor (Vldlr)-deficient

219 by binding to the two lipoprotein receptors, very-low-density lipoprotein receptor and apolipoprotein

220 ER2 (apolipoprotein E receptor 2) and VLDLR (very-low-density lipoprotein receptor).

221 rs, apolipoprotein E receptor 2 (Apoer2) and very-low-density lipoprotein receptor.

222 e gene expression for lipoprotein lipase and very-low-density lipoprotein receptor.

223 eceptors for Reelin, including integrins and very-low-density lipoprotein receptor/apolipoprotein E2

224 the brain involves the binding of Reelin to very-low-density lipoprotein receptors (VLDLR) and apoli

225 Very-low-density lipoprotein secretion, which is absent

226 atic free fatty acid oxidation, or decreased very-low-density lipoprotein secretion.

227 sity lipoprotein cholesterol subclasses, and very-low-density lipoprotein subclasses did not improve

228 events was also observed for several LDL and very-low-density lipoprotein subfractions but not for io

229 CVD/all-cause death, as were several LDL and very-low-density lipoprotein subfractions, albeit with a

230 mol/min for LowLF; P = .41) or production of very-low-density lipoprotein triacylglycerol from FFAs (

231 sociations were observed for extremely large very-low-density lipoprotein triglycerides (odds ratio [

232 ze and concentrations of LDLNMR and VLDLNMR (very-low-density lipoprotein) particles were negatively

233 Serum triglyceride, very-low-density lipoprotein, and apolipoprotein B level

234 ty lipoprotein, low-density lipoprotein, and very-low-density lipoprotein, can be easily separated an

235 poprotein, intermediate-density lipoprotein, very-low-density lipoprotein, lipoprotein (a), or chylom

236 They exist in three major classes: very-low-density lipoprotein, low-density lipoprotein, a

237 were used to assess insulin sensitivity and very-low-density lipoprotein-triglyceride (VLDL-TG) secr

238 rate decreased by 27% +/- 7% (P < .01); and very-low-density lipoprotein-triglyceride secretion rate

239 plasma total, high-density lipoprotein, and very-low-density lipoprotein/low-density lipoprotein cho

240 rocessed human milk and O-glycoproteins from very-low-density-lipoprotein (vLDL) particles.

241 Here we show that maternal very-low-density-lipoprotein (VLDL) receptor deletion in

242 protein (HDL) yields 4-6% of the LDL signal, very-low-density-lipoprotein (VLDL) yields 1-3%, and hum

243 , particularly in the cholesterol content of very-low-density lipoproteinparticles.

244 n the hepatic secretion of apoB-100-carrying very low density lipoproteins (VLDL) and a decrease in t

245 core lipid in the assembly and secretion of very low density lipoproteins (VLDL) has been of interes

246 HDL) particles to form triglyceride-enriched very low density lipoproteins (VLDL) has not been identi

247 The major protein component in secreted very low density lipoproteins (VLDL) is apoB, and it is

248 accelerated hepatic fatty acid oxidation and very low density lipoproteins (VLDL) secretion.

249 transient depression of hepatic secretion of very low density lipoproteins (VLDL).

250 riglyceride into plasma through secretion of very low density lipoproteins (VLDL).

251 c reticulum (ER) and is further lipidated to very low density lipoproteins (VLDL).

252 iating FFA uptake or triglyceride release as very low density lipoproteins (VLDL).

253 sma from apoA-I(-/-) mice or purified low or very low density lipoproteins but readily opacified HDL.

254 arily because of its role in the assembly of very low density lipoproteins by the liver and chylomicr

255 the secretion of cholesteryl ester-enriched very low density lipoproteins by the liver.

256 poB-48-carrying remnants of chylomicrons and very low density lipoproteins in the plasma.

257 ally derived chylomicrons and injected human very low density lipoproteins to the same extent as obse

258 ch was due to a decrease in the secretion of very low density lipoproteins.

259 creased hepatic secretion of TG into nascent very low density lipoproteins.

260 t dictates the synthesis of chylomicrons and very low density lipoproteins.

261 (HDL) to the proatherogenic low-density and very low-density lipoproteins (LDL and VLDL).

262 Procollagens, pre-chylomicrons, and pre-very low-density lipoproteins (pre-VLDLs) are too big to

263 DL are further isolated by precipitating the very low-density lipoproteins (VLDL) and low-density lip

264 (CE), and triglyceride (TG) from plasma and very low-density lipoproteins (VLDL) was used to measure

265 Raman signature of single optically trapped very low-density lipoproteins (VLDL), a subclass of TGRL

266 re to triglyceride-rich lipoproteins such as very low-density lipoproteins (VLDL).

267 Excessive secretion of triglyceride-rich very low-density lipoproteins (VLDL-TG) contributes to d

268 epatitis C virus (HCV) and triglyceride-rich very low-density lipoproteins (VLDLs) both are secreted

269 ip between CD36 expression and serum HDL and very low-density lipoproteins (VLDLs) levels was also ex

270 ccomplished primarily through the actions of very low-density lipoproteins (VLDLs).

271 lipoproteins, low-density lipoproteins, and very low-density lipoproteins contained elevated apoA-I

272 Rs of very low-density lipoproteins-apoB and very low-density lipoproteins triglycerides or on postpr

273 cholesterol to triglycerides ratio (1.52) in very low-density lipoproteins with elevated levels of sm

274 plasmic reticulum export of chylomicrons and very low-density lipoproteins, but not collagen XII.

275 ) dictates the formation of chylomicrons and very low-density lipoproteins, two major lipoprotein pre

276 by the inability to produce chylomicrons or very low-density lipoproteins, with the absence of apoli

277 Alirocumab had no effects on FCRs or PRs of very low-density lipoproteins-apoB and very low-density

278 poC-III and apoC-IV levels were decreased in very low-density lipoproteins.

279 in B (apoB)-containing lipoproteins (hepatic very-low density lipoproteins), which leads to hyperlipi

280 Very-low-density lipoproteins (VLDL) are metabolic precu

281 Very-low-density lipoproteins (VLDL) is a hallmark of me

282 in a manner that parallels the formation of very-low-density lipoproteins (VLDL).

283 fasting triacylglycerol in chylomicrons and very-low-density lipoproteins (VLDLs) (P = 0.004), reduc

284 actor ANOVA) in plasma (P = 0.023) and large very-low-density lipoproteins (VLDLs) (P = 0.016) and po

285 at transfers alpha-tocopherol (vitamin E) to very-low-density lipoproteins (VLDLs).

286 ty liver as a result of reduced secretion of very-low-density lipoproteins (VLDLs).

287 was observed in systolic BP (7.1 mm Hg) and very-low-density lipoproteins (VLDLs; 5.16 mg/dL) in gro

288 ipoproteins, including low-density (LDL) and very-low-density lipoproteins and chylomicrons.

289 studies with [(3)H]cholesteryl ether-labeled very-low-density lipoproteins demonstrated that the HL/E

290 triglyceride secretion, lower lipidation of very-low-density lipoproteins, and increased lipid dropl

291 B level, concentration and particle size of very-low-density lipoproteins, concentration of low-dens

292 suggesting that it arises from lipolysis of very-low-density lipoproteins.

293 of HCV E2 protein with human and bovine LPs (very low density, low density, and high density) enhance

294 mate the size of the components, we derive a very low density of 0.8(- 0.1)+0.2 g cm(-3).

295 ined by the expression on their surface of a very low density of CD44 (CD44(v.low) cells), can inhibi

296 Despite the very low density of the complexes at the cell surface, E

297 Internalization of apoE-containing very low density protein (VLDL) by hepatocytes in vivo a

298 ocytes presents capsular polysaccharide in a very low density that exhibits considerable plasticity a

299 adic Creutzfeldt-Jakob disease (CJD) bind to very low-density (VLDL) and low-density (LDL) lipoprotei

300 osae), a slow growing climax tree, occurs at very low densities, whereas J. copaia (Bignoniaceae) is